Drugs / Trivalent P2-VP8 Subunit Rotavirus Vaccine
Trivalent P2-VP8 Subunit Rotavirus Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02646891 | Feb 2016 → Sep 2017 | — | PATH | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent P2-VP8 Subunit Rotavirus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02646891 ↗ |
| Known as | P2-VP8 subunit rotavirus vaccine | “This is is a study of a parenteral trivalent rotavirus vaccine (P2-VP8 subunit rotavirus vaccine).” NCT02646891 ↗ |
| Known as | P2-VP8 vaccine | “The P2-VP8 vaccine tested in this study was developed by Dr. Taka Hoshino at National Institute of Allergy and Infectious Diseases (NIAID).” NCT02646891 ↗ |
| Known as | trivalent P2-VP8 vaccine | “The trivalent P2-VP8 vaccine was well tolerated, with promising anti-P2-VP8 IgG and neutralising antibody responses across the three vaccine P types.” PMID 32251641 ↗ Apr 2020 |
| Route | Intramuscular | “three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine” NCT02646891 ↗ |